Comparative Pharmacology
Head-to-head clinical analysis: ORTHO NOVUM 1 50 28 versus ORTHO NOVUM 1 80 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORTHO NOVUM 1 50 28 versus ORTHO NOVUM 1 80 21.
ORTHO-NOVUM 1/50 28 vs ORTHO-NOVUM 1/80 21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive; suppresses gonadotropin secretion (FSH, LH) via estrogen and progestin, inhibiting ovulation, increasing cervical mucus viscosity, and altering endometrial structure.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin (FSH, LH) release from pituitary, inhibiting ovulation. Increases viscosity of cervical mucus, impeding sperm penetration. Induces endometrial thinning, reducing implantation likelihood.
One tablet (1 mg norethindrone/50 mcg mestranol) orally once daily for 21 days, followed by 7 days of placebo tablets (inactive) for a 28-day cycle.
One tablet orally once daily for 21 consecutive days, followed by 7 days off therapy.
None Documented
None Documented
Norethindrone: 5-12 h (mean 8 h); Mestranol: 12-24 h (mean 18 h); steady-state reached within 5-7 days
Norethindrone terminal half-life: 8-11 hours; Mestranol (ethinyl estradiol pro-drug) terminal half-life: 10-15 hours (metabolite ethinyl estradiol). Clinical context: Steady-state reached in 5-7 days; once-daily dosing maintains therapeutic levels.
Renal: ~50-60% as metabolites; fecal: ~30-40% as metabolites; biliary: <10%
Renal: ~60% (metabolites, primarily glucuronide and sulfate conjugates), Fecal: ~40% (biliary excretion of metabolites). Unchanged drug negligible.
Category C
Category C
Hormonal Contraceptive
Hormonal Contraceptive